BIOPSYCHOSOCIAL APPROACHES TO OBSESSIVE-COMPULSIVE, BODY IMAGE AND EATING DISORDERS
Dr Nicola Acevedo, Neuroscientist and Research Fellow
Swinburne University of Technology, Melbourne, Australia
& Consultant, Neurotech Insights, Melbourne, Australia &
Director, BioAutism, Melbourne, Australia & Vice-President
Australasian Brain Stimulation Society
RESEARCHER PROFILE
Filmed in Melbourne, Australia | December 2025
Dr Nicola Acevedo is a Neuroscientist and Research Fellow with extensive expertise in developing novel therapeutics for neurological and psychiatric disorders, contributing to more than ten clinical trials. She specialises in brain stimulation and psychedelic treatments for obsessive-compulsive disorder (OCD) and related conditions, with a strong commitment to advancing personalised, evidence-based neurobiological therapies for severe psychiatric illness. Her approach integrates biopsychosocial and person-centred principles to improve treatment access and mental health outcomes.
Nicola completed her PhD on deep brain stimulation for treatment-refractory OCD- described as a “tour de force”- producing eight first-author peer-reviewed publications and multiple international collaborations and papers. She now leads research in psilocybin-assisted psychotherapy for OCD, body dysmorphic disorder, and anorexia nervosa. Her work has been presented at leading international forums including Oxford and Harvard University, and the Royal Australian and New Zealand College of Psychiatrists Congress.
Alongside her research, Nicola holds leadership positions across brain stimulation, OCD, and ethics committees, serves on a peer review board, and is Director of the charity BioAutism Ltd. She also provides mentorship and supervision, with a commitment to supporting junior researchers. Her contributions have been recognised with the Early Career Researcher (ECR) Excellence Award from Biological Psychiatry Australia. As an ECR, Nicola is driven by the potential to innovate and make an impact in national mental health services.
Source: Supplied
https://orcid.org/0000-0003-3059-3620
-
Clinical pathways for acute care in Tasmanian Emergency Departments
Assoc Prof Viet Tran has built Emergency Medicine Research in Tasmania from the ground up, which has culminated in the success of a AUD$3 million Australian Government Medical Research Futures Fund grant looking into the Implementation of Clinical Pathways for Acute Care in Tasmania project. Dr Tran is also the Emergency Medicine Discipline lead within the Tasmanian School of Medicine and has key roles to play within Emergency Medicine training. He feels privileged to be able to teach and mentor across the whole spectrum of becoming a doctor, from watching students grow into junior doctors, senior registrar and as fellow medical specialists.
-
Integrated Oral Health Care
Dr Ajesh George is a Professor of Interprofessional Oral Health in the School of Nursing and Midwifery, Western Sydney University (WSU) and Honorary Professor in the School of Dentistry at The University of Sydney. He is a dentist with extensive experience in integrated oral health care and is a renowned expert globally in providing oral health training to non-dental professionals and translating oral health guidelines into their practice. Dr George is also the Director and Co-founder of the “Australian Centre for Integration of Oral Health” (ACIOH) which is a leading national research centre led by WSU in collaboration with various partners including universities, health services and professional organisations.
-
Pancreatic and lung cancers driven by mutations in the cancer gene KRAS
Dr Mara Zeissig is a recently appointed Lab Head within the Tumour Inflammation and Immunotherapy Program at the South Australian immunoGENomics Cancer Institute (SAiGENCI).
Her research focuses on studying immune evasion mechanisms in lung and pancreatic cancers to identify novel ways to increase response to immunotherapy. Her expertise is in genetically engineered mouse models of lung cancer, CRISPR-Cas9 screening technologies and T cell based immunotherapies (e.g Checkpoint inhibitors).
